DR. DATSONS LABS | ELDER PHARMA | DR. DATSONS LABS/ ELDER PHARMA |
|||
---|---|---|---|---|---|
P/E (TTM) | x | -10.9 | -0.2 | - | View Chart |
P/BV | x | 0.2 | 0.1 | 160.9% | View Chart |
Dividend Yield | % | 0.0 | 0.0 | - |
![]() ![]() |
EQUITY SHARE DATA | |||||
---|---|---|---|---|---|
DR. DATSONS LABS Mar-14 |
ELDER PHARMA Jun-14 |
DR. DATSONS LABS/ ELDER PHARMA |
5-Yr Chart Click to enlarge
|
||
High | Rs | 126 | 380 | 33.1% | |
Low | Rs | 31 | 188 | 16.4% | |
Sales per share (Unadj.) | Rs | 133.0 | 491.2 | 27.1% | |
Earnings per share (Unadj.) | Rs | 0.2 | -3.2 | -4.8% | |
Cash flow per share (Unadj.) | Rs | 6.6 | 14.4 | 45.9% | |
Dividends per share (Unadj.) | Rs | 0 | 0 | - | |
Dividend yield (eoy) | % | 0 | 0 | - | |
Book value per share (Unadj.) | Rs | 128.8 | 376.5 | 34.2% | |
Shares outstanding (eoy) | m | 31.66 | 20.54 | 154.1% | |
Bonus/Rights/Conversions | FCCB | - | - | ||
Price / Sales ratio | x | 0.6 | 0.6 | 101.8% | |
Avg P/E ratio | x | 516.1 | -89.3 | -578.2% | |
P/CF ratio (eoy) | x | 11.8 | 19.7 | 60.1% | |
Price / Book Value ratio | x | 0.6 | 0.8 | 80.5% | |
Dividend payout | % | 0 | 0 | - | |
Avg Mkt Cap | Rs m | 2,477 | 5,833 | 42.5% | |
No. of employees | `000 | NA | NA | - | |
Total wages/salary | Rs m | 56 | 2,179 | 2.6% | |
Avg. sales/employee | Rs Th | NM | NM | - | |
Avg. wages/employee | Rs Th | NM | NM | - | |
Avg. net profit/employee | Rs Th | NM | NM | - |
INCOME DATA | |||||
---|---|---|---|---|---|
Net Sales | Rs m | 4,211 | 10,089 | 41.7% | |
Other income | Rs m | 79 | 257 | 30.7% | |
Total revenues | Rs m | 4,289 | 10,346 | 41.5% | |
Gross profit | Rs m | 569 | -792 | -71.8% | |
Depreciation | Rs m | 204 | 361 | 56.6% | |
Interest | Rs m | 430 | 2,756 | 15.6% | |
Profit before tax | Rs m | 13 | -3,653 | -0.3% | |
Minority Interest | Rs m | 0 | 0 | - | |
Prior Period Items | Rs m | -2 | 0 | - | |
Extraordinary Inc (Exp) | Rs m | 0 | 3,713 | 0.0% | |
Tax | Rs m | 6 | 125 | 4.9% | |
Profit after tax | Rs m | 5 | -65 | -7.3% | |
Gross profit margin | % | 13.5 | -7.8 | -172.0% | |
Effective tax rate | % | 48.0 | -3.4 | -1,402.0% | |
Net profit margin | % | 0.1 | -0.6 | -17.6% |
BALANCE SHEET DATA | |||||
---|---|---|---|---|---|
Current assets | Rs m | 6,852 | 9,240 | 74.2% | |
Current liabilities | Rs m | 6,711 | 9,998 | 67.1% | |
Net working cap to sales | % | 3.3 | -7.5 | -44.6% | |
Current ratio | x | 1.0 | 0.9 | 110.5% | |
Inventory Days | Days | 161 | 46 | 347.3% | |
Debtors Days | Days | 318 | 60 | 531.3% | |
Net fixed assets | Rs m | 3,673 | 10,124 | 36.3% | |
Share capital | Rs m | 317 | 206 | 153.9% | |
"Free" reserves | Rs m | 3,761 | 5,582 | 67.4% | |
Net worth | Rs m | 4,078 | 7,734 | 52.7% | |
Long term debt | Rs m | 1,671 | 4,889 | 34.2% | |
Total assets | Rs m | 12,633 | 22,882 | 55.2% | |
Interest coverage | x | 1.0 | -0.3 | -316.5% | |
Debt to equity ratio | x | 0.4 | 0.6 | 64.8% | |
Sales to assets ratio | x | 0.3 | 0.4 | 75.6% | |
Return on assets | % | 3.4 | 11.8 | 29.3% | |
Return on equity | % | 0.1 | -0.8 | -13.9% | |
Return on capital | % | 7.7 | 22.3 | 34.4% | |
Exports to sales | % | 22.9 | 3.0 | 753.4% | |
Imports to sales | % | 14.3 | 0.4 | 3,346.3% | |
Exports (fob) | Rs m | 964 | 307 | 314.4% | |
Imports (cif) | Rs m | 602 | 43 | 1,396.5% | |
Fx inflow | Rs m | 964 | 307 | 314.4% | |
Fx outflow | Rs m | 607 | 125 | 484.5% | |
Net fx | Rs m | 357 | 181 | 196.9% |
CASH FLOW | |||||
---|---|---|---|---|---|
From Operations | Rs m | 1,345 | 11,754 | 11.4% | |
From Investments | Rs m | -2,256 | -561 | 402.4% | |
From Financial Activity | Rs m | -1,200 | -6,762 | 17.7% | |
Net Cashflow | Rs m | -2,111 | 4,432 | -47.6% |
Indian Promoters | % | 4.5 | 39.6 | 11.4% | |
Foreign collaborators | % | 0.0 | 0.0 | - | |
Indian inst/Mut Fund | % | 0.0 | 7.5 | - | |
FIIs | % | 1.4 | 16.8 | 8.0% | |
ADR/GDR | % | 0.0 | 0.0 | - | |
Free float | % | 94.1 | 36.1 | 260.7% | |
Shareholders | 20,807 | 16,479 | 126.3% | ||
Pledged promoter(s) holding | % | 0.0 | 77.6 | - |
Compare DR. DATSONS LABS With: DIVIS LABORATORIES GLENMARK PHARMA AUROBINDO PHARMA FRESENIUS KABI ONCO. FDC LTD.
Compare DR. DATSONS LABS With: ACTAVIS (US) MYLAN (US) ADCOCK INGRAM (S. Africa) TEVA PHARMA (Israel)
| |
Indian share markets continued to trade on a positive note during closing hours and ended their session near day's high.
Should you subscribe to the IPO of MSPC Limited?
Should you subscribe to the IPO of MSPC Limited?
Should you apply for the IPO of state-run military aircraft maker Hindustan Aeronautics?
Should you apply for the IPO of Bharat Dynamics, India's first state-owned missile manufacturer?
Should you subscribe to the IPO of Apollo Micro Systems Ltd?
More Views on NewsWhat we can learn from one of the greatest traders to have ever lived.
What to do after every trade.
Should you invest in growth stocks or value stocks to make strong returns in this market?
This corner of the market could provide more returns than blue chips in 2020.
2019 will be remembered as the year of great money-making IPOs...
More